Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: European Surgery 4/2017

01.08.2017 | case report

Hypercalcemia resistant to cinacalcet caused by a mediastinal hyperplastic parathyroid gland in a renal transplant patient

verfasst von: MD Manabu Okada, MD Kenta Futamura, MD, PhD Takahisa Hiramitsu, MD Makoto Tsujita, MD, PhD Norihiko Goto, MD, PhD Shunji Narumi, MD, PhD Yoshihiko Watarai, MD Toshihiro Ichimori, MD, PhD Yoshihiro Tominaga

Erschienen in: European Surgery | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Renal hyperparathyroidism is a common complication in patients with chronic kidney disease. Cinacalcet, a kind of calcimimetic, has been reported to be an effective and safe treatment option in renal transplant patients with hyperparathyroidism. However, some patients require parathyroidectomy due to resistance to cinacalcet treatment. It is uncertain when we should give up treatment with cinacalcet and perform parathyroidectomy for persistent hyperparathyroidism.

Case report

We experience the first documented case in which cinacalcet-resistant hypercalcemia was caused by a mediastinal hyperplastic parathyroid gland after renal transplantation. The patient received total parathyroidectomy with autograft 4 years before renal transplantation. The levels of serum calcium and parathyroid hormone were controlled well with 25 mg daily of cinacalcet. Despite continuous treatment with cinacalcet, the patient developed hypercalcemia, hypercalciuria and nephrocarcinosis after renal transplantation. A mediastinal parathyroid lesion was revealed by imaging. Eventually, parathyroidectomy was performed for the mediastinal gland for the purpose of preventing new stone formation in the renal graft.

Conclusion

It was suggested that prompt parathyroidectomy is preferable rather than prolonged medical treatment for hypercalcemia resistant to cinacalcet caused by persistent hyperparathyroidism after renal transplantation. Furthermore, we should be extremely careful about hypercalcinuria and nephrocalcinosis when we prescribe cinacalcet for patients under hypercalcemia.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Dey V, Farrah TE, Traynor JP, Spalding EM, Robertson SE, Geddes CC. Symptomatic fracture risk in the renal replacement therapy population. Nephorol Dial Transplant. 2016. doi: 10.​1093/​ndt/​gfw222. Epub ahead of print. Dey V, Farrah TE, Traynor JP, Spalding EM, Robertson SE, Geddes CC. Symptomatic fracture risk in the renal replacement therapy population. Nephorol Dial Transplant. 2016. doi: 10.​1093/​ndt/​gfw222. Epub ahead of print.
2.
Zurück zum Zitat Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109. CrossRefPubMed Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109. CrossRefPubMed
3.
Zurück zum Zitat Tassone F, Guarnieri A, Castellano E, Baffoni C, Attanasio R, Borretta G. Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(8):3069–73. CrossRefPubMed Tassone F, Guarnieri A, Castellano E, Baffoni C, Attanasio R, Borretta G. Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J Clin Endocrinol Metab. 2015;100(8):3069–73. CrossRefPubMed
4.
Zurück zum Zitat Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7. CrossRefPubMed Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7. CrossRefPubMed
5.
Zurück zum Zitat Copley JB, Wüthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2011;25(1):24–39. CrossRefPubMed Copley JB, Wüthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2011;25(1):24–39. CrossRefPubMed
7.
8.
Zurück zum Zitat Toro Prieto FJ, Bernal Blanco G, Navarro García M, Cabello Chaves V, Garcíajiménez R, Pereira Palomo P, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc. 2009;41(6):2144–7. CrossRefPubMed Toro Prieto FJ, Bernal Blanco G, Navarro García M, Cabello Chaves V, Garcíajiménez R, Pereira Palomo P, et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc. 2009;41(6):2144–7. CrossRefPubMed
9.
Zurück zum Zitat Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010;42(7):2503–8. CrossRefPubMed Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010;42(7):2503–8. CrossRefPubMed
10.
Zurück zum Zitat Paschoalin RP, Torregrosa JV, Barros X, Durán CE, Campistol JM. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplant Proc. 2012;44(8):2376–8. CrossRefPubMed Paschoalin RP, Torregrosa JV, Barros X, Durán CE, Campistol JM. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplant Proc. 2012;44(8):2376–8. CrossRefPubMed
11.
Zurück zum Zitat Borchhardt KA, Heinzl H, Mayerwöger E, Hörl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation. 2008;86(7):919–24. CrossRefPubMed Borchhardt KA, Heinzl H, Mayerwöger E, Hörl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation. 2008;86(7):919–24. CrossRefPubMed
12.
Zurück zum Zitat Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20(7):1315–9. CrossRefPubMed Serra AL, Schwarz AA, Wick FH, Marti HP, Wüthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20(7):1315–9. CrossRefPubMed
13.
Zurück zum Zitat Okada M, Tominaga Y, Izumi K, Nobata H, Yamamoto T, Hiramitsu T, et al. Tertiary hyperparathyroidism resistant to cinacalcet treatment. Ther Apher Dial. 2011;15:33–7. CrossRefPubMed Okada M, Tominaga Y, Izumi K, Nobata H, Yamamoto T, Hiramitsu T, et al. Tertiary hyperparathyroidism resistant to cinacalcet treatment. Ther Apher Dial. 2011;15:33–7. CrossRefPubMed
14.
Zurück zum Zitat Messa P, Regalia A, Alfieri CM, Cresseri D, Forzenigo L, Gandolfo MT, et al. Current indications to parathyroidectomy in CKD patients before and after renal transplantation. J Nephrol. 2013;26(6):1025–32. CrossRefPubMed Messa P, Regalia A, Alfieri CM, Cresseri D, Forzenigo L, Gandolfo MT, et al. Current indications to parathyroidectomy in CKD patients before and after renal transplantation. J Nephrol. 2013;26(6):1025–32. CrossRefPubMed
15.
Zurück zum Zitat Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18. CrossRefPubMed Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18. CrossRefPubMed
16.
Zurück zum Zitat Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15(3):770–9. CrossRefPubMed Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15(3):770–9. CrossRefPubMed
17.
Zurück zum Zitat Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17. CrossRefPubMed Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17. CrossRefPubMed
18.
Zurück zum Zitat Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35(6):1226–37. CrossRefPubMed Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35(6):1226–37. CrossRefPubMed
19.
Zurück zum Zitat Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Narumi S, et al. Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg. 2016;40(3):600–6. CrossRefPubMed Yamamoto T, Tominaga Y, Okada M, Hiramitsu T, Tsujita M, Narumi S, et al. Characteristics of persistent hyperparathyroidism after renal transplantation. World J Surg. 2016;40(3):600–6. CrossRefPubMed
20.
Zurück zum Zitat Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479–86. CrossRefPubMed Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479–86. CrossRefPubMed
21.
Zurück zum Zitat Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1(2):323–6. CrossRefPubMed Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1(2):323–6. CrossRefPubMed
22.
Zurück zum Zitat Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006;109(3):339–65. CrossRefPubMed Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006;109(3):339–65. CrossRefPubMed
23.
Zurück zum Zitat Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25. CrossRefPubMed Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25. CrossRefPubMed
24.
Zurück zum Zitat Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800–7. CrossRefPubMed Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16(3):800–7. CrossRefPubMed
25.
Zurück zum Zitat Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36–45. CrossRefPubMedPubMedCentral Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3(1):36–45. CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Lee HH, Kim AJ, Ro H, Jung JY, Chang JH, Chung W, et al. Sequential changes of vitamin D level and parathyroid hormone after kidney transplantation. Transplant Proc. 2016;48(3):897–9. CrossRefPubMed Lee HH, Kim AJ, Ro H, Jung JY, Chang JH, Chung W, et al. Sequential changes of vitamin D level and parathyroid hormone after kidney transplantation. Transplant Proc. 2016;48(3):897–9. CrossRefPubMed
27.
Zurück zum Zitat Rodriguez M, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int. 1991;40(6):1063–8. CrossRefPubMed Rodriguez M, Felsenfeld AJ, Llach F. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy. Kidney Int. 1991;40(6):1063–8. CrossRefPubMed
28.
Zurück zum Zitat Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58(2):753–61. CrossRefPubMed Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58(2):753–61. CrossRefPubMed
29.
Zurück zum Zitat Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13(2):551–8. PubMed Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13(2):551–8. PubMed
30.
Zurück zum Zitat Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, Russmann S, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8(4):803–10. CrossRefPubMed Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, Russmann S, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8(4):803–10. CrossRefPubMed
31.
Zurück zum Zitat Seager CM, Srinivas TR, Flechner SM. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Ann Transplant. 2013;18:31–5. CrossRefPubMed Seager CM, Srinivas TR, Flechner SM. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Ann Transplant. 2013;18:31–5. CrossRefPubMed
32.
Zurück zum Zitat Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Sarfati E, et al. Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. Nephrol Dial Transplant. 2005;20(12):2865. CrossRefPubMed Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Sarfati E, et al. Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia. Nephrol Dial Transplant. 2005;20(12):2865. CrossRefPubMed
33.
Zurück zum Zitat Schlosser K, Endres N, Celik I, Fendrich V, Rothmund M, Fernández ED. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J Surg. 2007;31(10):1947–53. CrossRefPubMed Schlosser K, Endres N, Celik I, Fendrich V, Rothmund M, Fernández ED. Surgical treatment of tertiary hyperparathyroidism: the choice of procedure matters! World J Surg. 2007;31(10):1947–53. CrossRefPubMed
34.
Zurück zum Zitat Hsieh TM, Sun CK, Chen YT, Chou FF. Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am Surg. 2012;78(5):600–6. PubMed Hsieh TM, Sun CK, Chen YT, Chou FF. Total parathyroidectomy versus subtotal parathyroidectomy in the treatment of tertiary hyperparathyroidism. Am Surg. 2012;78(5):600–6. PubMed
35.
Zurück zum Zitat Park JH, Kang SW, Jeong JJ, Nam KH, Chang HS, Chung WY, et al. Surgical treatment of tertiary hyperparathyroidism after renal transplantation: a 31-year experience in a single institution. Endocr J. 2011;58(10):827–33. CrossRefPubMed Park JH, Kang SW, Jeong JJ, Nam KH, Chang HS, Chung WY, et al. Surgical treatment of tertiary hyperparathyroidism after renal transplantation: a 31-year experience in a single institution. Endocr J. 2011;58(10):827–33. CrossRefPubMed
36.
Zurück zum Zitat Tominaga Y, Matsuoka S, Uno N, Tsuzuki T, Hiramitsu T, Goto N, et al. Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients. World J Surg. 2010;34(6):1312–7. CrossRefPubMed Tominaga Y, Matsuoka S, Uno N, Tsuzuki T, Hiramitsu T, Goto N, et al. Removal of autografted parathyroid tissue for recurrent renal hyperparathyroidism in hemodialysis patients. World J Surg. 2010;34(6):1312–7. CrossRefPubMed
Metadaten
Titel
Hypercalcemia resistant to cinacalcet caused by a mediastinal hyperplastic parathyroid gland in a renal transplant patient
verfasst von
MD Manabu Okada
MD Kenta Futamura
MD, PhD Takahisa Hiramitsu
MD Makoto Tsujita
MD, PhD Norihiko Goto
MD, PhD Shunji Narumi
MD, PhD Yoshihiko Watarai
MD Toshihiro Ichimori
MD, PhD Yoshihiro Tominaga
Publikationsdatum
01.08.2017
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 4/2017
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-017-0484-y